BIOTECH COMPANY AMGEN 3Q PROFIT DROPS 63 PERCENT ON SETTLEMENT OTHER CHARGES AND HIGHER COSTS
October 25, 2011
TRENTON, N.J. — Amgen Inc. said Monday that its third-quarter profit plunged by more than 60 percent, mainly because of a $780 million charge for a planned settlement of multiple federal and state investigations of marketing and other practices. The world’s largest biotech drugmaker also had higher costs for administration and production, but it still beat Wall Street estimates excluding one ...
Full Story Below
Rapid Response
Free Case Evaluation
The Help You Need,
When You Need it Most
More from Settlement News Directory
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
